SCHEMBL2560189

SCHEMBL2560189

Cc1cnc(N2CCC(C(N)=O)CC2)nc1-c1cccc(N(C)C)c1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.58
TDP1 Q9NUW8 1/20 0.44
EIF2AK4 Q9P2K8 1/20 0.41
RAB9A P51151 3/20 0.41
NPC1 O15118 2/20 0.41
AOC3 Q16853 2/20 0.41
PDE4D Q08499 1/20 0.41
KDM4E B2RXH2 2/20 0.41
GAA P10253 1/20 0.41
TSHR P16473 1/20 0.41
CASP1 P29466 1/20 0.41
CASP7 P55210 1/20 0.41
HSD17B10 Q99714 1/20 0.41
NEK2 P51955 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PKM P14618 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2557117 0.89 SMN1; SMN2 (0.57) SMN1; SMN2TDP1EIF2AK4RAB9ANPC1
SCHEMBL2554399 0.85 SMN1; SMN2 (0.61) SMN1; SMN2AOC3
SCHEMBL2557199 0.82 BRAF (0.43) SMN1; SMN2RAB9ANPC1AOC3KDM4E
SCHEMBL2573220 0.82 SMN1; SMN2 (0.60) SMN1; SMN2TDP1RAB9ANPC1KDM4E
SCHEMBL2560486 0.82 SMN1; SMN2 (0.66) SMN1; SMN2TDP1RAB9ANPC1KDM4E
SCHEMBL2553912 0.76 SMN1; SMN2 (0.60) SMN1; SMN2TDP1RAB9ANPC1PDE4D
SCHEMBL2554131 0.76 SMN1; SMN2 (0.66) SMN1; SMN2RAB9ANPC1LMNA
SCHEMBL2554360 0.75 SMN1; SMN2 (0.57) SMN1; SMN2TDP1EIF2AK4RAB9ANPC1
SCHEMBL2557161 0.74 SMN1; SMN2 (0.64) SMN1; SMN2TDP1RAB9ANPC1KDM4E
SCHEMBL2559606 0.73 SMN1; SMN2 (1.00) SMN1; SMN2RAB9ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US claimed
WO-2011130515-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-10-20 WO claimed
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US disclosed
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US disclosed
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2013-04-18 US disclosed
WO-2011130515-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2011-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130096160-A1 ARYLTHIAZOLYL PIPERIDINES AND RELATED COMPOUNDS AS MODULATORS OF SURVIVAL MOTOR NEURON (SMN) PROTEIN PRODUCTION SMN1; SMN2, MTPN, MORF4L1 SMN1; SMN2 1/4885TDP1 914/4885EIF2AK4 229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.